 |
0 Diseases |  |
1 Trial |
|
1 Trial |  |
3 News |  |
| 12» |
- | samuraciclib (CT7001) / Carrick Therap
New P1/2 trial: SONIC: Samuraciclib in Combination With Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic Cancer (clinicaltrials.gov) - Jun 24, 2026
P1/2, N=67, Not yet recruiting, Sponsor: University Health Network, Toronto
- samuraciclib (CT7001) / Carrick Therap
Epigenetic reprogramming of stromal-epithelial crosstalk to improve immunotherapy response in pancreatic ductal adenocarcinoma (Section 49) - Mar 17, 2026 - Abstract #AACR2026AACR_9396;
Ongoing spatial multiplex imaging and RNA-seq analyses aim to correlate in vivo immune and stromal changes with in vitro findings, supporting rational combination strategies. This epigenetic screening platform provides a predictive framework to evaluate compounds that overcome CAF-mediated immune exclusion and modulate the tumor microenvironment, offering new avenues to enhance PDAC responsiveness to diverse immunotherapies.
- samuraciclib (CT7001) / Carrick Therap
Targeting high risk osteosarcoma: MYC modulation alters metastasis (Section 45) - Mar 17, 2026 - Abstract #AACR2026AACR_3249;
Nevertheless, the top hit of the screen, samuraciclib, convincingly reverses MYC activity and the associated metastatic phenotype and is undergoing additional testing in metastatic OS mouse models and a canine clinical trial is under development. Correlative biology such as spatial transcriptomics will be used to guide the translation of samuraciclib to patients with high risk osteosarcoma.
- || giredestrant (RG6171) / Roche
Trial completion date, Trial primary completion date: MORPHEUS BC: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer (clinicaltrials.gov) - Dec 21, 2025
P1/2, N=316, Recruiting, Sponsor: Hoffmann-La Roche
Correlative biology such as spatial transcriptomics will be used to guide the translation of samuraciclib to patients with high risk osteosarcoma. Trial completion date: Nov 2027 --> May 2029 | Trial primary completion date: Nov 2027 --> May 2029
- | mevociclib (SY-1365) / Syros, samuraciclib (CT7001) / Carrick Therap, SY-5609 / Syros
Journal: Functional insight into cyclin-dependent kinase (CDK)7 via chemical inhibition of the priority fungal pathogen Cryptococcus neoformans. (Pubmed Central) - Dec 10, 2025
The antifungal activity of SY-1365 was also markedly enhanced in combination with membrane-targeting antifungals. Together, our findings highlight CDK7 inhibitors as valuable tools to study CDK7 function in Cn and as potentially promising antifungals in combination with licensed antifungals.
- samuraciclib (CT7001) / Carrick Therap
Results of the phase 2 SUMIT-BC study, a randomized controlled trial of the cyclin-dependent kinase 7 inhibitor (CDK7i) samuraciclib with fulvestrant in advanced hormone receptor positive (HR+) breast cancer after a CDK4/6 inhibitor (CDK4/6i) (Exhibit Hall) - Nov 5, 2025 - Abstract #SABCS2025SABCS_2297;
P2
The most common AEs were dose-related GI AEs. Pharmacokinetics of the new tablet formulation were acceptable.
- | Veppanu (vepdegestrant) / Arvinas, Pfizer
Trial completion date, Trial primary completion date: C4891024: TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C) (clinicaltrials.gov) - Oct 31, 2025
P1/2, N=11, Active, not recruiting, Sponsor: Pfizer
Pharmacokinetics of the new tablet formulation were acceptable. Trial completion date: Nov 2025 --> Apr 2026 | Trial primary completion date: Nov 2025 --> Apr 2026
- ||| samuraciclib (CT7001) / Carrick Therap
Trial completion, Trial completion date: SUMIT-BC: A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants (clinicaltrials.gov) - Sep 29, 2025
P2, N=60, Completed, Sponsor: Carrick Therapeutics Limited
Trial completion date: Nov 2025 --> Apr 2026 | Trial primary completion date: Nov 2025 --> Apr 2026 Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Aug 2025
- || samuraciclib (CT7001) / Carrick Therap
Trial primary completion date: SUMIT-BC: A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants (clinicaltrials.gov) - Jul 31, 2025
P2, N=60, Active, not recruiting, Sponsor: Carrick Therapeutics Limited
Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Aug 2025 Trial primary completion date: Jun 2025 --> Mar 2025
- samuraciclib (CT7001) / Carrick Therap
Patient selection biomarkers for CDK7 inhibitor samuraciclib (SAM; CT7001) combined with selective estrogen receptor degrader (SERD) in hormone receptor-positive advanced breast cancer (HR+ ABC) post-CDK4/6 inhibitor (CDK4/6i) (Hall B0) - Mar 29, 2025 - Abstract #ESMOBC2025ESMO_BC_599;
P1/2
The observed outcomes in this small dataset appear greater than the anticipated prognostic impact of these factors [O'Leary et al. JNCI 2021; Robertson et al.
- Ibrance (palbociclib) / Pfizer, samuraciclib (CT7001) / Carrick Therap
Homogeneous bioluminescent immunoassay for hKi-67 provides a simple and robust screening tool for antiproliferative agents (Section 10; Poster Board No: 11) - Mar 25, 2025 - Abstract #AACR2025AACR_8280;
JNCI 2021; Robertson et al. This assay enables efficient screening of antiproliferative agents, demonstrating exceptional performance in assessing antiproliferative activity across multiple mechanisms of action.We evaluated the Lumit
- Ibrance (palbociclib) / Pfizer, TY-2699a / TYK Medicines
A potent CDK7 inhibitor TY-2699a suppresses palbociclib-resistant breast cancer and has the potential for combination with chemotherapy or immunotherapy in solid tumors (Section 34; Poster Board No: 9) - Mar 25, 2025 - Abstract #AACR2025AACR_2887;
Consistent with the in vitro results, a 40 mg/kg dose of palbociclib almost completely failed to inhibit tumor growth in the xMCF-7/Palbo-R mouse model of breast cancer. TY-2699a at a dose of 6 mg/kg significantly inhibited tumor growth.
- ||| Veppanu (vepdegestrant) / Arvinas, Pfizer
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: C4891024: TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C) (clinicaltrials.gov) - Mar 6, 2025
P1/2, N=11, Active, not recruiting, Sponsor: Pfizer
TY-2699a at a dose of 6 mg/kg significantly inhibited tumor growth. Recruiting --> Active, not recruiting | N=67 --> 11 | Trial completion date: Jan 2027 --> Nov 2025 | Trial primary completion date: Jul 2026 --> Nov 2025
- | samuraciclib (CT7001) / Carrick Therap
Trial completion date, Trial primary completion date: SUMIT-ELA: A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer (clinicaltrials.gov) - Feb 21, 2025
P1/2, N=49, Active, not recruiting, Sponsor: Carrick Therapeutics Limited
Recruiting --> Active, not recruiting | N=67 --> 11 | Trial completion date: Jan 2027 --> Nov 2025 | Trial primary completion date: Jul 2026 --> Nov 2025 Trial completion date: Jun 2025 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
- || samuraciclib (CT7001) / Carrick Therap
Trial completion date, Trial primary completion date: SUMIT-BC: A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants (clinicaltrials.gov) - Feb 21, 2025
P2, N=60, Active, not recruiting, Sponsor: Carrick Therapeutics Limited
Trial completion date: Jun 2025 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025 Trial completion date: Jun 2025 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Jun 2025
- ||| giredestrant (RG6171) / Roche
Enrollment change: MORPHEUS BC: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer (clinicaltrials.gov) - Feb 18, 2025
P1/2, N=316, Recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Jun 2025 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Jun 2025 N=510 --> 316
- || giredestrant (RG6171) / Roche
Trial primary completion date: MORPHEUS BC: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer (clinicaltrials.gov) - Feb 5, 2025
P1/2, N=510, Recruiting, Sponsor: Hoffmann-La Roche
N=510 --> 316 Trial primary completion date: Apr 2026 --> Nov 2027
- || giredestrant (RG6171) / Roche
Trial completion date: MORPHEUS BC: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer (clinicaltrials.gov) - Jan 6, 2025
P1/2, N=510, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Apr 2026 --> Nov 2027 Trial completion date: Oct 2026 --> Nov 2027
- vepdegestrant (ARV-471) / Arvinas, Pfizer, Verzenio (abemaciclib) / Eli Lilly
Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, Plus Abemaciclib in ER-Pos/Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced or Metastatic Breast Cancer: TACTIVE-U Prelim Phase 1b Results (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1804;
- Orserdu (elacestrant) / Menarini, samuraciclib (CT7001) / Carrick Therap
Cyclin-dependent kinase 7 (CDK7) inhibitor samuraciclib combined with selective estrogen receptor degrader (SERD) elacestrant in advanced HR+ breast cancer after CDK4/6i: dose escalation data from the Phase 1b/2 SUMIT-ELA study (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_828;
- || samuraciclib (CT7001) / Carrick Therap
Enrollment closed: SUMIT-BC: A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants (clinicaltrials.gov) - Oct 15, 2024
P2, N=60, Active, not recruiting, Sponsor: Carrick Therapeutics Limited
Trial completion date: Oct 2026 --> Nov 2027 Recruiting --> Active, not recruiting
- | samuraciclib (CT7001) / Carrick Therap
Enrollment closed: SUMIT-ELA: A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer (clinicaltrials.gov) - Sep 4, 2024
P1/2, N=49, Active, not recruiting, Sponsor: Carrick Therapeutics Limited
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- samuraciclib (CT7001) / Carrick Therap
Fulvestrant with or without the cyclin-dependent kinase 7 (CDK7) inhibitor samuraciclib in advanced hormone receptor positive (HR+) breast cancer after CDK4/6 inhibition: Phase II SUMIT-BC study. (Hall A; Poster Bd #: 101a) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2555;
P2
Coombes et al. Nature Comms 2023.
- || Veppanu (vepdegestrant) / Arvinas, Pfizer
Trial completion date, Trial primary completion date: C4891024: TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C) (clinicaltrials.gov) - Apr 14, 2024
P1/2, N=67, Recruiting, Sponsor: Pfizer
Nature Comms 2023. Trial completion date: Aug 2027 --> Jan 2027 | Trial primary completion date: Feb 2027 --> Jul 2026
- || Veppanu (vepdegestrant) / Arvinas, Pfizer
Trial completion date, Trial primary completion date: C4891024: TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C) (clinicaltrials.gov) - Mar 25, 2024
P1/2, N=67, Recruiting, Sponsor: Pfizer
Trial completion date: Aug 2027 --> Jan 2027 | Trial primary completion date: Feb 2027 --> Jul 2026 Trial completion date: Feb 2027 --> Aug 2027 | Trial primary completion date: Aug 2026 --> Feb 2027
- samuraciclib (CT7001) / Carrick Therap
The liquid biomarker thymidine kinase activity reflecting proliferation rate can provide guidance in drug development and address Project Optimus (Section 45) - Mar 5, 2024 - Abstract #AACR2024AACR_9083;
After initiation of samuraciclib treatment, a CDK7 inhibitor, a significant reduction in TKa levels in blood from metastatic breast cancer (MBC) patients was observed, indicating inhibition of cell cycle progression...MBC patients monitored >3 months and showing low TKa levels have very low likelihood of progression within 30- to 60 days, <2% and <6%, respectively. TKa is a translational liquid biomarker that bridges results between preclinical and clinical studies, providing fundamental information for drug development decision making.
- | Veppanu (vepdegestrant) / Arvinas, Pfizer
Phase classification: C4891024: TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C) (clinicaltrials.gov) - Feb 23, 2024
P1/2, N=67, Recruiting, Sponsor: Pfizer
TKa is a translational liquid biomarker that bridges results between preclinical and clinical studies, providing fundamental information for drug development decision making. Phase classification: P2 --> P1/2
- |||| Veppanu (vepdegestrant) / Arvinas, Pfizer
New P1/2 trial, New P2 trial: C4891024: TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C) (clinicaltrials.gov) - Feb 15, 2024
P2, N=67, Recruiting, Sponsor: Pfizer
- ||| Veppanu (vepdegestrant) / Arvinas, Pfizer
Enrollment open, Phase classification: C4891024: TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C) (clinicaltrials.gov) - Jan 30, 2024
P2, N=67, Recruiting, Sponsor: Pfizer
Phase classification: P2 --> P1/2 Not yet recruiting --> Recruiting | Phase classification: P1b/2 --> P2
- samuraciclib (CT7001) / Carrick Therap
Phase classification: SUMIT-ELA: A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer (clinicaltrials.gov) - Dec 14, 2023
P1/2, N=48, Recruiting, Sponsor: Carrick Therapeutics Limited
Not yet recruiting --> Recruiting | Phase classification: P1b/2 --> P2 Phase classification: P1b/2 --> P1/2
- || samuraciclib (CT7001) / Carrick Therap
New P1/2 trial: SUMIT-ELA: A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer (clinicaltrials.gov) - Dec 14, 2023
P1/2, N=48, Recruiting, Sponsor: Carrick Therapeutics Limited
- | samuraciclib (CT7001) / Carrick Therap
Journal: Active growth signaling promotes senescence and cancer cell sensitivity to CDK7 inhibition. (Pubmed Central) - Nov 22, 2023
We show that CDK7i, by samuraciclib, induces a permanent cell-cycle exit, known as senescence, without promoting DNA damage signaling or cell death...Reverting a growth-promoting mutation in PIK3CA to wild type decreases sensitivity to CDK7i. Our work establishes that enhanced growth alone promotes CDK7i sensitivity, providing an explanation for why some cancers are more sensitive to CDK inhibition than normally growing cells.
- Orserdu (elacestrant) / Menarini, samuraciclib (CT7001) / Carrick Therap
SUMIT-ELA: Phase 1b/2 combination of cyclin-dependent kinase 7 inhibitor (CDK7i) samuraciclib and selective estrogen receptor degrader (SERD) elacestrant in advanced hormone receptor positive (HR+) breast cancer after CDK4/6i (Hall 2-3) - Nov 4, 2023 - Abstract #SABCS2023SABCS_1094;
Secondary endpoints are tolerability, clinical benefit response at 24 weeks, overall response rate, duration of response, best percent change in tumor size, pharmacokinetics and correlations between ctDNA detectable ESR1 and TP53 mutations and efficacy/safety finding in this patient population. The study opened for recruitment in June 2023.
- samuraciclib (CT7001) / Carrick Therap
SUMIT-BC: Phase 2 randomized study of fulvestrant with or without the cyclin-dependent kinase 7 inhibitor (CDK7i) samuraciclib in advanced hormone receptor positive (HR+) breast cancer after CDK4/6i (Hall 2-3) - Nov 4, 2023 - Abstract #SABCS2023SABCS_1093;
QoL and correlations between ctDNA detectable TP53 mutations and efficacy/safety finding in this patient population will be reported. The study opened for recruitment in June 2023.
- vepdegestrant (ARV-471) / Arvinas, Pfizer
TACTIVE-U: phase 1b/2 umbrella study of vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, combined with other anticancer treatments in ER (Hall 2-3) - Nov 4, 2023 - Abstract #SABCS2023SABCS_962;
P1/2, P1b/
The cyclin-dependent kinase (CDK)4/6 inhibitors abemaciclib and ribociclib are approved in combination with an aromatase inhibitor or fulvestrant, or as monotherapy (abemaciclib), for ER+/HER2- advanced or metastatic breast cancer...Vepdegestrant is being evaluated in combination with abemaciclib (sub-study A; NCT05548127), ribociclib (sub-study B; NCT05573555), and samuraciclib (sub-study C)...The phase 2 portion of each sub-study will further evaluate the antitumor activity of the combinations; the primary endpoint is objective response and secondary endpoints include antitumor activity (CBR and DOR), PFS, overall survival, safety, plasma concentration of study drugs, and changes in circulating tumor DNA. Future combination sub-studies will be included in TACTIVE-U.
- | Biomarker, Journal, IO biomarker: Unraveling TIMP1: a multifaceted biomarker in colorectal cancer. (Pubmed Central) - Oct 16, 2023
Furthermore, TIMP1 expression was positively correlated with that of ferroptosis-related genes, such as GPX4 and HSPA5. TIMP1 can be used as a biomarker for colorectal cancer and is associated with the immunological microenvironment, drug sensitivity, and ferroptosis inhibition in this disease.
- |||||| samuraciclib (CT7001) / Carrick Therap
Clinical, Metastases: New results from a phase I study of the CDK7-inhibitor #samuraciclib examining dose escalation and expansion cohorts in patients with advanced #breastcancer published in @NatureComms from @MatthewGKrebs @RMJesel @stuartamcintyre @DrSachaHowell @BCJoyceO. https://t.co/1fqK7QNbj5 (Twitter) - Aug 3, 2023
- | samuraciclib (CT7001) / Carrick Therap
Journal: Disruption of CDK7 signaling leads to catastrophic chromosomal instability coupled with a loss of condensin-mediated chromatin compaction. (Pubmed Central) - Jul 31, 2023
Notably, the regulation of condensin subunit gene expression is independent of super-enhancers. Together, these studies reveal a new role for CDK7 in sustaining chromatin configuration by ensuring the expression of condensin genes, including SMC2.
- |||| samuraciclib (CT7001) / Carrick Therap
New P2 trial: SUMIT-BC: A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants (clinicaltrials.gov) - Jul 27, 2023
P2, N=60, Recruiting, Sponsor: Carrick Therapeutics Limited
- TY-2699a is a highly potent CDK7 inhibitor to abolish dysfunctional tumor cell cycle for clinical development (Section 9; Poster Board #10) - Mar 14, 2023 - Abstract #AACR2023AACR_8576;
P1
Currently, trilaciclib, palbociclib, ribociclib, and abemaciclib that bear dual specificities against CDK4 and CDK6 have been approved for clinical usage, and more CDK4/6 targeted agents are actively under clinical evaluations, among which, TY-302, a novel CDK4/6 inhibitor being developed by TYK Medicines, is under Phase II trial (NCT04433494)...Several CDK7 targeted agents, such as SY-5609 and Samuraciclib (CT7001), are under development...# Shengli Dong and Apeng Liang contributed equally to this work. * Jun Li, Shengli Dong and Apeng Liang are the correspondent authors.
- samuraciclib (CT7001) / Carrick Therap
Defining modulators of response to samuraciclib, a CDK7 inhibitor for breast cancer (Section 15; Poster Board #5) - Mar 14, 2023 - Abstract #AACR2023AACR_3838;
In conclusion, our findings highlight the importance of an active mTOR/PI3K pathway in promoting response to Samuraciclib. This may help guide patient treatments and development of effective combination therapies.
- ||| samuraciclib (CT7001) / Carrick Therap
Trial completion, First-in-human: CT7001_001: Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies (clinicaltrials.gov) - Jan 27, 2023
P1/2, N=124, Completed, Sponsor: Carrick Therapeutics Limited
This may help guide patient treatments and development of effective combination therapies. Active, not recruiting --> Completed
- || giredestrant (RG6171) / Roche
Trial completion date, Trial primary completion date: MORPHEUS BC: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer (clinicaltrials.gov) - Nov 15, 2022
P1/2, N=510, Recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Trial completion date: Apr 2027 --> Oct 2026 | Trial primary completion date: Oct 2026 --> Apr 2026
- ||| samuraciclib (CT7001) / Carrick Therap
Enrollment change, First-in-human: CT7001_001: Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies (clinicaltrials.gov) - Oct 19, 2022
P1/2, N=124, Active, not recruiting, Sponsor: Carrick Therapeutics Limited
Trial completion date: Apr 2027 --> Oct 2026 | Trial primary completion date: Oct 2026 --> Apr 2026 N=250 --> 124
- |||||| samuraciclib (CT7001) / Carrick Therap
Discussing emerging agents for new targets in #breastcancer. CDK7 kick starts phosphorylation of cell cycle says @amitjainmd with chair @wadavidal @OncLive @OncLiveSOSS @west_cancer @uthsc @OneOncology #samuraciclib tp53 predictive (Twitter) - Jun 17, 2022
- ||||| samuraciclib (CT7001) / Carrick Therap, fulvestrant / Generic mfg.
Discussing new agents on the #breastcancer horizon Dr Pat LoRusso includes cdk7 blocker samuraciclib being looked at with fulvestrant @OncLive @OncLiveSOSS with chair @DrEricWiner @ASCOPres @YaleCancer (Twitter) - Jun 14, 2022
- |||||| samuraciclib (CT7001) / Carrick Therap
Clinical, Combination therapy: "Study of #Samuraciclib a first-in-class, oral, selective inhibitor of #CDK7, in combination with fulvestrant in patients with advanced hormone receptor-positive, HER2-negative Breast Cancer" interesante revisión de la Dra. Denisse Lee #SABCS @FUCAMM @OncoAlert @BCTrials (Twitter) - Mar 5, 2022
- samuraciclib (CT7001) / Carrick Therap
Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC) () - Feb 13, 2022 - Abstract #MESABCS2022MESABCS_41;
- |||| samuraciclib (CT7001) / Carrick Therap
Promising anti-tumour activity of the CDK7-inhibitor samuraciclib (plus fulvestrant) in pre-treated ER-positive/HER2-negative metastatic breast cancer https://t.co/ZkTvQKcUsP (Twitter) - Jan 22, 2022
- ||||| samuraciclib (CT7001) / Carrick Therap
Clinical: The #OncoAlertTopTweet #SABCS21 Day3⃣by our @OncoAlert 🚨 #BreastCancer #BCSM faculty @stolaney1 🇺🇸 Fulvestrant + samuraciclib (CDK7i) in pts with metastatic HR+ BC with prior cdk 4/6i (n=31) Best, @weoncologists (Twitter) - Dec 10, 2021